Canaccord Genuity Maintains Buy on Neuronetics, Raises Price Target to $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $8.
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $8.